Low-intensity chronic inflammation is responsible for many diseases including insulin resistance and certain heart muscle diseases. Investigating new molecular mechanisms implicated in this process could lead to new pharmacological targets to prevent or reduce the impact of these conditions. More specifically, our group aims to investigate the involvement of peroxisomal proliferator-activated receptor (PPAR)beta/delta agonists, AMP-activated protein kinase activators and oleic acid on these pathways in preventing low-intensity chronic inflammation and its associated pathologies.
Our primary aim is to identify new pharmacological targets that would rupture this link between inflammation and diseases such as insulin resistance and heart muscle disease.
We form part of the Centre for Biomedical Network Research on Diabetes and Associated Metabolic Diseases (CIBERDEM) and are a recognised research group by Government of Catalonia (2017SGR-124).
- The study of new mechanisms by which PPARbeta/delta agonists reduce inflammation and insulin resistance.
- The evaluation of new pharmacological targets for the prevention of diabetic heart muscle disease.
- Research on new pharmacological targets for the treatment and prevention of diabetic heart muscle disease in animal type 1 diabetes mellitus models.
- The evaluation of new pharmacological targets involved in the development of diabetes and the potential to develop new medicines to treat diabetes.
- The study of the mechanisms involved in the low birth weight caused by endoplasmic reticulum stress on the placenta.
- To develop heme-regulated inhibitor (HRI) activator medicines to increase hepatic and serum fibroblast growth factor 21 (FGF21) levels for the treatment of metabolic diseases.
- To evaluate the effects of PPARb/d agonists in preventing diabetic heart disease.
- To establish new determinants connecting inflammation with insulin resistance.
- To establish a possible association between FGF21 and endoplasmic reticulum stress and low birth weight.
Area/Field of expertise
Our area of expertise is pharmacological biochemistry in inflammation and insulin resistance.
Our methodology includes the conduct of in vivo and in vitro studies. We have expertise in the use of various in vivo models (obesity and insulin resistance models induced by fat or fructose diet; animal heart disease models with over-expression of TNFα in the heart). We use these to investigate glucose intolerance, fatty liver (liver triglyceride levels, Oil-Red O and eosin-haematoxylin staining, immunohistochemistry), cardiac hypertrophy (echocardiography, immunohistochemistry), inflammation (expression of inflammatory cytokines in tissues, DNA binding activity of NF-κB and other proinflammatory transcription factors, protein levels) and metabolites (diacylglycerol, ceramides).
We have also gained extensive experience in in vitro studies with various mouse (myotubes, cardiomyocytes, hepatocytes and adipocytes) and human cell lines (skeletal muscle cells, adipocytes, cardiomyocytes and hepatocytes) as well as in the study of primary cultures. In these cultures, we analyse fatty acid oxidation, glucose uptake, microRNA, inflammatory markers, adipokines and endoplasmic reticulum stress markers. We have also conducted gene silencing using small interfering RNA or gene over-expression.
- Barroso E, Rodríguez-Rodríguez R, Zarei M, Pizarro-Degado J, Planavila A, Palomer FX, Villarroya F and Vazquez M SIRT3 deficiency exacerbates fatty liver by attenuating the HIF1a-LIPIN 1 pathway and increasing CD36 through Nrf2. CELL COMMUN SIGNAL . 18(1): 147-147.
- Zarei M, Pizarro J, Barroso E, Palomer FX and Vazquez M Targeting FGF21 for the Treatment of Nonalcoholic Steatohepatitis. TRENDS PHARMACOL SCI . 41(3): 199-208.
- Palomer FX, Román-Azcona MS, Pizarro J, Planavila A, Villarroya F, Valenzuela-Alcaraz BI, Crispi F, Sepúlveda-Martínez Á, Miguel-Escalada I, Ferrer J, Nistal JF, García R, Davidson MM, Barroso E and Vazquez M SIRT3-mediated inhibition of FOS through histone H3 deacetylation prevents cardiac fibrosis and inflammation. signal transduction and targeted therapy . 5(1): 14-14.